Difference between revisions of "Rituximab-arrx (Riabni)"
Jump to navigation
Jump to search
(Created page with "'''Note: this is an FDA-approved biosimilar. The information below is reproduced from the Rituximab (Rituxan) page, except for the details of FDA indication.''' ==General...") |
Warner-admin (talk | contribs) m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp") |
||
| (9 intermediate revisions by 3 users not shown) | |||
| Line 6: | Line 6: | ||
<br>Extravasation: [[neutral]] | <br>Extravasation: [[neutral]] | ||
*[[Rituximab (Rituxan) desensitization protocol]] | *[[Rituximab (Rituxan) desensitization protocol]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
| − | *[[Acquired | + | *[[Acquired hemophilia A]] |
*[[Immune thrombocytopenia (ITP)]] | *[[Immune thrombocytopenia (ITP)]] | ||
*[[B-cell acute lymphoblastic leukemia]] | *[[B-cell acute lymphoblastic leukemia]] | ||
| Line 22: | Line 22: | ||
*[[Hairy cell leukemia]] | *[[Hairy cell leukemia]] | ||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
| − | *[[Hodgkin lymphoma]] | + | *[[Classical Hodgkin lymphoma]] |
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
*[[Inherited coagulopathy|Inherited coagulopathy with inhibitor]] | *[[Inherited coagulopathy|Inherited coagulopathy with inhibitor]] | ||
| Line 30: | Line 30: | ||
*[[Post-transplant lymphoproliferative disorder]] | *[[Post-transplant lymphoproliferative disorder]] | ||
*[[Primary mediastinal B-cell lymphoma]] | *[[Primary mediastinal B-cell lymphoma]] | ||
| − | *[[ | + | *[[Acquired thrombotic thrombocytopenic purpura]] |
*[[Transformed lymphoma]] | *[[Transformed lymphoma]] | ||
*[[Waldenström macroglobulinemia]] | *[[Waldenström macroglobulinemia]] | ||
| Line 36: | Line 36: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf Rituximab (Rituxan) package insert] | *[http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf Rituximab (Rituxan) package insert] | ||
| − | *[ | + | *[https://chemocare.com/druginfo/Rituximab.aspx Rituximab (Rituxan) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Rituximab.aspx Rituximab (Rituxan) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/rituximab-patient-drug-information Rituximab (Rituxan) patient drug information (UpToDate)]</ref> | ||
| Line 43: | Line 43: | ||
==Also known as== | ==Also known as== | ||
| − | *'''Brand | + | *'''Code name:''' ABP-798 |
| + | *'''Brand name:''' Riabni | ||
==References== | ==References== | ||
| Line 54: | Line 55: | ||
[[Category:Anti-CD20 antibodies]] | [[Category:Anti-CD20 antibodies]] | ||
| − | [[Category:Acquired | + | [[Category:Acquired hemophilia A medications]] |
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
[[Category:Burkitt lymphoma medications]] | [[Category:Burkitt lymphoma medications]] | ||
| Line 65: | Line 66: | ||
[[Category:Hairy cell leukemia medications]] | [[Category:Hairy cell leukemia medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
| − | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | [[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | ||
[[Category:Immune thrombocytopenia medications]] | [[Category:Immune thrombocytopenia medications]] | ||
| Line 74: | Line 75: | ||
[[Category:Post-transplant lymphoproliferative disorder medications]] | [[Category:Post-transplant lymphoproliferative disorder medications]] | ||
[[Category:Primary mediastinal B-cell lymphoma medications]] | [[Category:Primary mediastinal B-cell lymphoma medications]] | ||
| − | [[Category: | + | [[Category:Acquired thrombotic thrombocytopenic purpura medications]] |
[[Category:Transformed lymphoma medications]] | [[Category:Transformed lymphoma medications]] | ||
[[Category:Waldenström macroglobulinemia medications]] | [[Category:Waldenström macroglobulinemia medications]] | ||
Revision as of 12:12, 29 June 2024
Note: this is an FDA-approved biosimilar. The information below is reproduced from the Rituximab (Rituxan) page, except for the details of FDA indication.
General information
Class/mechanism: Anti-CD20 antibody, chimeric murine/human monoclonal IgG1 kappa, which binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), which is expressed on B-cells. The Fc domain recruits immune effector functions to mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
- Acquired hemophilia A
- Immune thrombocytopenia (ITP)
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Castleman disease
- Chronic lymphocytic leukemia
- CNS lymphoma
- Cold agglutinin disease
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Hairy cell leukemia
- HIV-associated lymphoma
- Classical Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Inherited coagulopathy with inhibitor
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Acquired thrombotic thrombocytopenic purpura
- Transformed lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Rituximab (Rituxan) package insert
- Rituximab (Rituxan) patient drug information (Chemocare)[1]
- Rituximab (Rituxan) patient drug information (UpToDate)[2]
History of changes in FDA indication
To be completed
Also known as
- Code name: ABP-798
- Brand name: Riabni
References
Categories:
- Drugs
- Intravenous medications
- Neutral
- Protein expression-specific medications
- Anti-CD20 antibodies
- Acquired hemophilia A medications
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Castleman disease medications
- CNS lymphoma medications
- Chronic lymphocytic leukemia medications
- Cold agglutinin disease medications
- Diffuse large B-cell lymphoma medications
- Follicular lymphoma medications
- Hairy cell leukemia medications
- HIV-associated lymphoma medications
- Classical Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Immune thrombocytopenia medications
- Inherited coagulopathy medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Acquired thrombotic thrombocytopenic purpura medications
- Transformed lymphoma medications
- Waldenström macroglobulinemia medications
- FDA approved in 2020
- Biosimilars
- WHO Essential Cancer Medicine